Financial reports
ARS
2023 FY
Annual report to shareholders
1 Apr 24
10-K
2023 FY
Annual report
29 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-K/A
2022 FY
Annual report (amended)
25 Oct 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
4 Apr 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
Current reports
8-K
Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results
28 Mar 24
8-K
Departure of Directors or Certain Officers
22 Mar 24
8-K
Departure of Directors or Certain Officers
21 Mar 24
8-K/A
Entry into a Material Definitive Agreement
26 Jan 24
8-K
Entry into a Material Definitive Agreement
25 Jan 24
8-K
Regulation FD Disclosure
5 Jan 24
8-K
Departure of Directors or Certain Officers
27 Dec 23
8-K
Aspira Women’s Health Provides a Development Update on its Portfolio of Noninvasive Tests for Endometriosis
6 Dec 23
8-K
Aspira Women’s Health Reports Third Quarter 2023 Financial Results
13 Nov 23
8-K
Other Events
23 Oct 23
Registration and prospectus
S-3
Shelf registration
22 Apr 24
424B3
Prospectus supplement
11 Apr 24
S-1
IPO registration
5 Apr 24
D
$6.49 mm in options / securities to be acquired, sold $6.49 mm, 7 investors
7 Feb 24
S-8
Registration of securities for employees
26 Jan 24
424B5
Prospectus supplement for primary offering
26 Jan 24
424B5
Prospectus supplement for primary offering
24 Jul 23
424B5
Prospectus supplement for primary offering
29 Mar 23
424B5
Prospectus supplement for primary offering
10 Feb 23
424B5
Prospectus supplement for primary offering
24 Aug 22
Proxies
DEFA14A
Additional proxy soliciting materials
29 Mar 24
DEF 14A
Definitive proxy
29 Mar 24
DEFA14A
Additional proxy soliciting materials
3 Apr 23
DEF 14A
Definitive proxy
30 Mar 23
PRE 14A
Preliminary proxy
20 Mar 23
DEF 14A
Definitive proxy
28 Dec 22
PRER14A
Preliminary revised proxy
28 Dec 22
PRE 14A
Preliminary proxy
16 Dec 22
DEFR14A
Revised proxy
7 Jun 22
DEFA14A
Additional proxy soliciting materials
11 May 22
Other
EFFECT
Notice of effectiveness
12 Apr 24
EFFECT
Notice of effectiveness
29 Jan 21
CORRESP
Correspondence with SEC
26 Jan 21
UPLOAD
Letter from SEC
25 Jan 21
EFFECT
Notice of effectiveness
1 Oct 20
CORRESP
Correspondence with SEC
25 Sep 20
UPLOAD
Letter from SEC
24 Sep 20
EFFECT
Notice of effectiveness
7 Nov 17
CORRESP
Correspondence with SEC
3 Nov 17
UPLOAD
Letter from SEC
31 Oct 17
Ownership
SC 13G/A
Schultz Eric Adam
8 Apr 24
3
Sandra Milligan
4 Apr 24
4
Nicole Sandford
20 Feb 24
4
Torsten Hombeck
14 Feb 24
4
Minh Hoang Merchant
14 Feb 24
4
Nicole Sandford
30 Jan 24
4/A
Celeste Rachelle Fralick
29 Dec 23
4/A
Veronica GH Jordan
27 Dec 23
SC 13G
Schultz Eric Adam
26 Dec 23
3
ROBERT H DRYSDALE
8 Dec 23